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A B S T R A C T
Hormonal, metabolic, hemodynamic, vascular and immunological changes that occur during pregnancy can affect
the function of the eye. These changes are commonly transient, but in some cases they may be permanent and have conse-
quences even after childbirth. The ocular effects of pregnancy may be physiological or pathological and can be associated
with the development of new ocular pathology or may be modifications of pre-existing conditions. The most common
physiological changes are alterations of corneal sensitivity and thickness, decreased tolerance to contact lenses, decrea-
sed intraocular pressure, hemeralopia and refractive errors. Possible posterior segment changes include worsening of di-
abetic retinopathy, central serous chorioretinopathy, increased risk of peripheral vitreochorioretinal dystrophies and reti-
nal detachment. Thus, it should be kept in mind that the presence of any ocular symptoms in a pregnant woman requires
ophthalmologic examination and further management.
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Introduction
During pregnancy various changes in hormonal, im-
munological, metabolic, hematologic and cardiovascular
status can be observed. These modifications in turn
cause a number of alterations in the whole body includ-
ing the eye. Ocular changes in pregnancy are related to
adnexa of the eye, anterior and posterior segment and
can cause decreased intraocular pressure. The mentio-
ned ocular changes may be temporary, transitory, com-
pletely transient or in some cases even permanent. Like-
wise they may also be physiological or pathological.
Further these changes may be associated with the devel-
opment of new diseases or alternatively can cause alter-
ations in pre-existing conditions1–4. Additionally pathol-
ogy of pregnancy itself can further complicate present
ocular conditions5,6.
Nowadays a large number of young people including
women of childbearing age have shown great interest in
refractive surgery thus it should be emphasized that
pregnancy causes changes in the eye making the results
of any refractive surgery unpredictable. It is therefore
recommended that refractive procedures in pregnant
women be postponed till after delivery7.
Physiologic Ocular Changes Occurring
in Pregnancy
Sensitivity of the cornea is known to be decreased in
pregnancy, occurring mostly in the third trimester and
subsiding in the postpartum period. However some in-
vestigations failed to relate this decrease in corneal sen-
sitivity to the duration of gestation8,9. Increase in corneal
thickness observed in pregnant women may be the conse-
quence of corneal oedema resulting from increased water
retention during pregnancy1,4,9. Conversely some investi-
gations found no difference in corneal thickness of preg-
nant and non-pregnanat women10. Changes in corneal
curvature and steeping may also occur during pregnancy
particularly during the second and third trimesters. The-
se changes are usually reversible and resolved in the
postpartum period or after cessation of breastfeeding11.
Pregnant women appear to suffer more from lacrimal
dysfunction than non pregnant women; in both groups
the prevalence of tear dysfunction is more elevated in
women with higher parity12. As a result of altered tear
film, corneal oedema and changed corneal curvature con-
tact lens intolerance may occur even though they had
been successful contact lens wearers prior to pregnan-
cy11. In such cases it is recommended to wait several
weeks after delivery before prescribing a new refraction7.
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Although glaucoma is generally a disease of the el-
derly it may affect women of childbearing age13. Nowa-
days there is a trend for later childbirth and thus the fre-
quency of glaucoma during pregnancy may increase. A
decrease in intraocular pressure (IOP) has been observed
during pregnancy and often persists for several months
after delivery. The decrease in IOP can lead to changes in
women with pre-existing glaucoma which can improve
during this period. Various underlying mechanism pro-
pose to explain the cause of decrease in IOP during preg-
nancy, namely; an increase in outflow as a result of hor-
mone levels modification, a decrease in systemic vascular
resistance, decrease in episcleral venous pressure, in-
creased tissue elasticity and generalised acidemia during
pregnancy14. It is also possible that IOP is not in fact re-
duced during pregnancy but rather could be the result of
measurement error. The physiological changes in late
pregnancy may reduce corneoscleral rigidity, making the
results of applanation tonometry falsely low. Likewise an
increase in corneal thickness could also affect the mea-
sured values of IOP15. However it should be emphasized
that despite the apparent reduced IOP level in pregnant
women many glaucoma patients still need to continue
treatment since glaucoma damage may advance during
pregnancy and progressive visual field loss can occur14.
During pregnancy certain changes in the visual field
such as bitemporal loss, concentric constriction, and en-
larged blind spots can be observed. These changes are
generally asymptomatic and shown to be completely re-
versible, usually 10 days after delivery14. Several reasons
can explain this visual field loss. Magnetic resonance im-
aging studies show that the size of the pituitary gland in-
creases during a normal pregnancy16 and thus could
press and damage the optic chiasm causing bitemporal
visual field changes. Likewise, another cause of visual
field damage could be glaucoma or brain tumours14.
However, symptomatic patients inevitably require fur-
ther investigation and follow up.
Pre-Existing Ocular Conditions
and Pregnancy
Progression of diabetic retinopathy (DR) occurs at
least temporarily during pregnancy. Although the cause
of this progression is not entirely understood the consen-
sus is that this mechanism is multi-factorial with impor-
tant contributory factors including hyperglycaemia, du-
ration of diabetes before conception, baseline status of
retinopathy, rapid control of blood glucose during preg-
nancy, coexisting hypertension, preeclampsia and chan-
ges in retinal blood flow17,18. More recently there is grow-
ing evidence suggesting that in the progression of retino-
pathy activation and adaptation of the immune system
during gestation could also have certain role. It is estab-
lished that during pregnancy, certain components of the
immune system that are knowingly implicated in the
pathogenesis of DR are activated19,20. It is commonly be-
lieved that the severity of DR may regress at least to
some degree in the postpartum period although the rate
and timing of this regression is still relatively unknown.
Whilst the rate of regression of DR at the end of preg-
nancy or the postpartum period is substantial careful
monitoring of these patients is necessary to optimize the
vision and pregnancy outcomes21. Studies describe that
about 10% of women with diabetes without any signs of
retinopathy prior to pregnancy tend to develop some
background retinopathy during pregnancy. Furthermore
less than 0.2% of pregnant women with diabetes pro-
gressed to proliferative stages of the disease. It was re-
ported that as many as 50% with non-proliferative reti-
nopathy may develop an increase in retinopathy, often
improving by the third trimester and during breastfeed-
ing. Between 5 and 20% can develop proliferative chan-
ges, where women are at higher risk if they had non-pro-
liferative retinopathy at the beginning of pregnancy.
Patients with proliferative diabetic retinopathy (PDR)
showed a progression of the disease in as many as 45% of
cases. Laser treatment before pregnancy appears to sub-
stantially minimise this risk, whilst no recurrence of the
disease was reported if regression of proliferation was ob-
served prior to pregnancy22–24. Sight-threatening DR in
pregnancy is a rare disease yet it can have devastating
consequences for mother and child. Established sight-
-threatening retinopathy should therefore be treated at
an earlier stage in pregnant women compared to non-
-pregnant diabetics with a similar disease. Laser photo-
coagulation should be considered for pregnant women
with severe pre-proliferative diabetic retinopathy25. It
should be emphasized that DR should be carefully moni-
tored before conception and during pregnancy. All known
risk factors must be taken into account when planning
pregnancy in diabetic women and during the follow-up of
their retinopathy. Counselling addressing the risks of
retinopathy progression prior to planning pregnancy is
highly recommended. Careful eye examination before
and during the first trimester should be performed in
these patients in order to detect severe non-proliferative
DR or high-risk DR with prompt laser treatment if neces-
sary. Follow-up visits should be adapted according to the
severity of this complication. Macular oedema may also
develop or worsen during pregnancy and is generally
linked to women who have diabetes accompanied by
proteinuria and hypertension. It can spontaneously re-
gress postpartum and therefore should not be treated too
rapidly26. Given the fact that diabetes takes longer than
five years to develop morphological changes correspond-
ing to DR, women with gestational diabetes would not de-
velop this complication during pregnancy and therefore
fundus examination in these women is not obligatory de-
spite their glucose blood level27.
Major hormonal changes emerge during pregnancy.
The pituitary gland is one of the most affected organs
with altered anatomy and physiology followed by conse-
quential enlargement. Pituitary adenomas may cause
problems by their hormone secretion that affects the
mother and fetus as well as causing an increased risk of
tumour growth28. Pituitary adenomas can change size
and consequently cause changes in visual field, however
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are more often than not, asymptomatic. Clinically signifi-
cant tumour growth may occur in 2.7% of patients with
microadenomas, in 22.9% of patients with macroadeno-
mas without prior ablative treatment and 4.8% of those
with macroadenomas and previous ablative treatment.
Women with macroadenomas should have visual fields
assessed periodically during gestation. Thus, should
symptomatic tumour growth occur, reinstitution of the
dopamine agonist is usually successful in shrinking the
tumour. If the pregnancy is sufficiently advanced, in-
duced delivery is also an option whilst transsphenoidal
de-bulking is rarely necessary29. Some of the brain tu-
mours observed in pregnant women such as glioblasto-
mas, meningeomas and melanomas can also influence vi-
sion and cause visual field disturbances with symptoms
depending on the tumour location. However, it should be
noted that most do not show significant changes in be-
haviour during gestation30.
Among many women with non-infectious uveitis an
increase in disease activity within the first four months
of pregnancy occurs. The disease appears to be relatively
inactive in later pregnancy with a rebound within six
months of delivery31. Inflammatory eye diseases such as
uveitis can affect females during their reproductive pe-
riod. The first trimester and postpartum period may be
associated with an exacerbation of uveitis and therefore
it is important to have available medications that can
control the disease and do not cause miscarriage or fetal
abnormalities32. Many autoimmune diseases in females
are known to improve during pregnancy but worsen in
the postpartum period, since pregnancy induces immune
deviation promoting anti-inflammatory cytokines that
prevent immunological rejection of the allogenic fetus33,34.
It is confirmed that pregnancy is associated with im-
provement of some autoimmune diseases including rheu-
matoid arthritis and multiple sclerosis and with exacer-
bation of other autoimmune conditions such as systemic
lupus erythematosis. Female patients with uveitis may
require close control and if necessary treatment during
pregnancy as well as in the early postpartum period35,36.
Pregnant state may provoke the recurrence of ocular
toxoplasmosis. Acute toxoplasmic retinochoroiditis in
pregnancy could be a risk of transplacental transmission
due to potential parasitemia with detrimental effects on
the developing fetus37. Pregnancy causes a number of
physiological alterations in thyroid hormone metabo-
lism. Graves' disease often shows a characteristic course
in pregnancy with amelioration of thyrotoxicosis in the
second half of pregnancy and exacerbation after delivery.
In addition, transplacental passage of maternal TSH re-
ceptor antibodies may lead to thyrotoxicosis in the fetus
or newborn. The symptoms of thyrotoxicosis are impor-
tant as they represent a serious condition to both mother
and the fetus38. Multiple sclerosis, on the contrary has
been known to stabilise during pregnancy especially in
the final trimester, and then relapse usually in the first
three months postpartum. Some studies link this pattern
with estrogen levels39.
Pregnancy is known to cause refractive changes as a
result of various hormonal changes which occur during
pregnancy. These changes may persist for a few weeks
post-partum and during lactation7. There has been con-
cern that patients with high myopia are at a risk for de-
veloping retinal tears as they go through spontaneous
delivery. High myopia is not itself an indication for cesar-
ean section; however the patient should definately be ex-
amined after delivery. Furthermore the literature shows
that there is little evidence to support the belief that pre-
vious retinal surgery increases the risk of re-detachment
of the retina during spontaneous vaginal delivery40. Piz-
zarello researched the existence of worsening myopia in
pregnant women. In his study all women with com-
plaints of visual disturbances were found to have experi-
enced a myopic shift from pre-pregnancy levels with a re-
turn to near pre-pregnancy levels post partum41.
Ophthalmic Medications in Pregnancy
Insufficient data is available regarding the effect and
potential risk of ophthalmic medications on pregnancy,
the fetus and breast milk contamination42,43. Glaucoma
medications (beta blockers) are to be avoided or at least
used in the lowest possible dose especially in the first tri-
mester when the risk of teratogenesis is highest and
should be discontinued several days prior to delivery to
avoid beta-blockade in the infant. Carbonic anhydrase
inhibitors are known to have teratogenic effects and
should be avoided during pregnancy. Their application is
contraindicated in mothers who are breastfeeding be-
cause of the potential hepatic and renal effects to the in-
fant. However, acetazolamide has been reported to be
compatible with lactation according to the American
Academy of Paediatrics. Miotics (eg, pilocarpine, echo-
thiophate, carbachol) appear to be safe during pregnancy
whilst their toxicity during lactation is unknown. One
exception is demecarium, which is toxic and is contrain-
dicated in pregnancy and mothers who are breastfeed-
ing44. The widespread use of prostaglandin to induce la-
bour, terminate pregnancy and regulate menstruation
has raised concerns of its use in pregnant women45. How-
ever, according to some reports locally applied prosta-
glandine analogues have insufficient active ingredients
to cause adverse effects on the fetus whilst other reports
consider that the use of prostaglandin is generally con-
tra-indicated in pregnant women. This suggests that
they should be used cautiously during pregnancy and
should be discontinued several days before birth46. Occa-
sional use of mydriatic drops for the purposes of ocular
examination is considered to be safe; however repeated
use should be avoided due to potential teratogenic effects
of both parasympatholytics (eg, atropine) and sympatho-
mimetics (eg, epinephrine). Use of mydriatics is contra-
indicated in mothers who are breastfeeding because of
anticholinergic or hypertensive effects on the fetus. Cor-
ticosteroids are considered to be contraindicated even
though there are no known teratogenic effects of topical
steroids. They should however be avoided during breast-
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feeding since little is known about the risk of their appli-
cation during lactation. Antibiotics that are considered
safe during pregnancy include erythromicin, ophthalmic
tobramycin, ophthalmic gentamicin, polymyxin B and
the quinolones with the latter two showing to be safe
even during breastfeeding. The list of antibiotics that
should be avoided during pregnancy include: chloram-
phenicol, systemic gentamycin, neomiycin, rifampin.
Acyclovir is generally well tolerated in pregnant women.
Treatment using clinically recommended doses has low
toxic potential and no adverse effects have been reported
regarding its application during pregnancy44. There are
no known side effects of flouresecin and topical anaes-
thetics drops if used during pregnancy. Drugs against al-
lergies are used to treat inflammatory and allergic con-
junctivitis. Although data on ophthalmic antihistamine
use during pregnancy and their potential teratogenic
risk is very low the use of this group of ophthalmic drugs
during pregnancy is considered to be safe44,47.
Patients who are pregnant may require the use of
medication to supplement their treatment. However, to
ensure a decreased incidence of systemic absorption and
toxicity simple measures should be applied. Firstly, pre-
scribing the patient the lowest recommended dose and
secondly instructing the patient to correctly administer
medication to avoid adsorption by nasal mucosa.
Very little data has been published evaluating the risk
of using ophthalmic drugs during pregnancy. There is a
lack of meta-analyses and randomised controlled trials in
this area of study. Most of the available evidence is based
only on individual case reports and animal studies. As a
general rule, all drugs should be avoided if possible in the
first trimester since the risk of drug-induced foetal tera-
togenicity is highest during this period. Despite the lack
of data on the risks of eye drug application ophthalmolo-
gists should nonetheless continue to prescribe appropri-
ate treatments particularly when their expected benefits
to the mother outweigh the risk to the fetus.
Conclusion
It has been reported that the number of pregnant
women undergoing regular eye examinations is low. The
majority of pregnant women referred to ophthalmologist
are those with previously diagnosed high myopia. Most
ocular changes in pregnancy are physiological and re-
versible. Nevertheless, it is advised that such changes
should be registered and followed-up at least during
pregnancy and in the post-partum period. Pre-existing
ocular conditions require regular control at least three
times during the pregnancy and even more often in
women with pre-existing diabetes. In gestational diabe-
tes significant changes of the eye are not expected. High
myopia and previous retinal surgery are no longer an in-
dication for compulsory caesarean section; however still
require regular control by an obstetrician and ophthal-
mologist.
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OKO U TRUDNO]I
S A @ E T A K
Hormonske, metaboli~ke, hemodinamske, vaskularne i imunolo{ke promjene koje se doga|aju tijekom trudno}e
izme|u ostalog utje~u i na funkciju o~iju. Promjene na o~ima su obi~no prolazne, ali u nekim slu~ajevima mogu ostati
trajno s posljedicma koje se manifestiraju i nakon poroda. Promjene koje se javljaju na o~ima mogu biti fiziolo{ke ili
patolo{ke odnosno mogu biti povezane s nastankom i razvojem razvojem novih patolo{kih stanja oka ili mo`e do}i do
promjena ranijih ve} postoje}ih bolesti. Naj~e{}e fiziolo{ke promjene su pove}anje osjetljivosti ro`nice, zadebljanje ro`-
nice, smanjena tolerancija prilikom no{enja kontaktnih le}a, sni`enje o~nog tlaka, hemeralopia te promjene u refrakciji
oka. Promjene koje se mogu pojaviti na stra`njem segmentu oka uklju~uju pojavu i napredovanje dijabeti~ke retinopa-
tije, nastanak centralne serozne korioretinopatije, pove}ani rizik pojave perifernih vitreokorioretinalnih distrofija i
odvajanje mre`nice. Treba naglasiti da kod svih promjena na oku koje se jave tijekom trudno}e potreban pregled i
lije~enje oftalmologa.
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